Express Scripts' service provider subsidiary United BioSource secures PE investment

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/10255185_88)
(Image: Getty/10255185_88)

Related tags: Corporation, Health care

Avista Capital Partners has signed an agreement to acquire United BioSource (UBC), adding another pharmaceutical service provider to the firm’s list of current and historical investments.

Headquartered in New York, Avista Capital Partners is private equity (PE) firm with approximately $6bn under management.

The company declined to comment on the acquisition of UBC, a wholly-owned subsidiary of Express Scripts, who also declined to comment.

Blue Bell, PA-headquartered UBC provides clinical, safety, and commercialization services with 13 locations in the US, Canada, and Europe.

Patrick Lindsay, UBC president, said in the press release:

"Avista's commitment to the healthcare industry makes them the ideal partner as we continue to improve patient care. Together, we will provide our clients, their patients, and their prescribers with innovative services that meet the demands of a dynamic industry​."

Investing in the healthcare sector

Avista has previously​ invested in service providers including INC Research, Charles River Laboratories, BioReliance Corporation, and Accellent, among others.

The laboratory product, supply chain, and service provider, VWR International – which was recently acquired​ by Avantor, Inc. – is listed under the firm’s current​ investments.

Given the industry’s strong fundamentals and outlook for continued growth, Avista believes the healthcare sector continues to be an attractive area for investment​,” the company states on its website.

In the press release, Rob Girardi, Partner of Avista Capital Partners, said: "We are excited to partner with UBC at this moment in the company's growth cycle, and look forward to leveraging both Avista's and UBC's expertise in the healthcare sector to deliver on the significant opportunities ahead​."

Related news

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more